PRZOOM - /newswire/ -
Palo Alto, CA, United States, 2007/10/16 - New analysis from Frost & Sullivan, U.S. Multiple Sclerosis Markets, reveals that the market earned revenues of $3.24 billion in 2006 and estimates this to reach $7.31 billion in 2013.
The multiple sclerosis (MS) market is undergoing a revolution with the imminent introduction of innovative therapies that will change the approach toward the treatment of the disease. This market evolution has not escaped the notice of pharmaceutical and biotechnology companies across various tiers, as they engage in a race to develop inventive and effective treatment options for MS.
New analysis from Frost & Sullivan (pharmaceuticals.frost.com), U.S. Multiple Sclerosis Markets, reveals that the market earned revenues of $3.24 billion in 2006 and estimates this to reach $7.31 billion in 2013.
If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants an overview of the latest analysis of the U.S. Multiple Sclerosis Markets, then send an email to Melina Trevino - Corporate Communications at melina.trevino[.]frost.com with the following information: your full name, company name, title, telephone number, email address, city, state, and country. We will send you the information via email upon receipt of the above information.
Big pharma, specialty pharma, niche pharma, biotechnology, and start-up companies could soon fill the vacuum created by the lack of an outstanding treatment option. The innovations will stand market participants in good stead, since healthcare providers are hoping to improve the standard of care and patient compliance.
"Conventional therapies have focused on managing the symptoms of the disease and delaying the progression," says Frost & Sullivan Research Analyst Barath Shankar S. "The side-effect profiles of these therapies have resulted in poor patient compliance and lower treatment rates."
The yawning gap between demand and supply of effective MS drugs has encouraged healthcare companies to devise newer ways of targeting and managing the progression of the disease. The pipeline for MS drugs is robust and includes drugs at various stages of development. They are expected to improve treatment rates and possibly, cure the disease.
"While traditional injection-based interferon therapies continue to remain the cornerstone of treatment, the next generation of therapies in development is dominated by vaccines and oral formulations that cater predominantly to the relapsing remitting type of MS," notes Shankar.
The market majors are working on potent combination therapies with interferons and other oral drugs. This could have a telling effect on the treatment paradigm of MS.
The unmet medical needs in primary progressive MS (PPMS) and secondary progressive MS (SPMS) segments are opening up significant market expansion opportunities for participants. Vendors are testing existing products for label expansion into other market segments, while simultaneously working on launching innovative therapies for the same purpose.
The U.S. Multiple Sclerosis Markets is part of the Pharmaceutical & Biotechnology Growth Partnership Service, which includes research service in the following markets: U.S. opioid and non-opioid pain management pharmaceuticals markets, Global CRO spending trends, and U.S. generic pharmaceuticals outlook. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants. Interviews with the press are available.
About Frost & Sullivan
Frost & Sullivan, the Growth Consulting Company, partners with clients to accelerate their growth. The company's Growth Partnership Services, Growth Consulting and Career Best Practices empower clients to create a growth focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents.